We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 21, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
INTEGRIN alpha(v)beta(6) FOR DIAGNOSIS/PROGNOSIS OF COLORECTAL CARCINOMA
METHOD, DEVICE AND SYSTEM FOR SPATIALLY CONTROLLING THE FORMATION OF A HYDROGEL ELECTROCHEMICALLY
METHOD FOR PREDICTING CANCER PROGRESSION BY NANOMECHANICAL PROFILING
N-ACETYL GLUCOSAMINE AS A BIOMARKER OF MS DISEASE COURSE